公开(公告)号：WO2023073645A1

公开(公告)日：2023-05-04

申请号：PCT/IB2022/060413

申请日：2022-10-28

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  MORPHOSYS AG

发明人： HUSZAR, Dennis ,  PROSCURSHIM, Igor

IPC分类号： A61P35/00 ,  A61K31/34 ,  A61K39/395 ,  A61P35/02

摘要： The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer in patients in need thereof. The methods comprise administering to a patient in need a small ubiquitin-like modifier (SUMO) activating enzyme (SAE) inhibitor, such as [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxy-cyclopentyl]methyl sulfamate (Compound I-263a) or a pharmaceutically acceptable salt, in combination with one or more anti-CD19 antibodies. Also provided are medicaments for use in treating cancer.

公开(公告)号：WO2023042096A1

公开(公告)日：2023-03-23

申请号：PCT/IB2022/058670

申请日：2022-09-14

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： HOEFINGHOFF, Joris ,  LEIDENMUEHLER, Peter ,  GANGADHARAN, Bagirath ,  HAIDER, Norbert ,  NAGY, Andras ,  LI, Zhaoyang

IPC分类号： A61K38/47 ,  A61M5/44 ,  A61P37/00 ,  C07K16/06

摘要： Provided is a concentrated pharmaceutical formulation of an immune globulin (IG), and convenient methods for the subcutaneous administration of this pharmaceutical formulation in a warmed state. Such products can be used in methods of treating IG-treatable diseases or conditions. Also provided are combinations, compositions and kits containing an immune globulin (IG) composition and a soluble hyaluronidase composition formulated for subcutaneous administration.

公开(公告)号：WO2023009700A2

公开(公告)日：2023-02-02

申请号：PCT/US2022/038640

申请日：2022-07-28

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  SHAPIRO, Gary

发明人： TAKE, Chihiro ,  KASSAI, Yoshiaki ,  HE, Xingyue ,  KUHN, Chantal

IPC分类号： C07K16/28 ,  C07K16/30 ,  C12N15/86 ,  A61K2039/5156 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/523 ,  C07K14/5443 ,  C07K14/7051 ,  C07K2317/622 ,  C07K2319/03

摘要： Disclosed herein are engineered immune cells that specifically recognizes mesothelin and expresses IL-15 and optionally CCL19. Also disclosed herein are isolated nucleic acid molecules comprising a polynucleotide encoding a chimeric antigen receptor (CAR) comprising an antibody that specifically recognizes mesothelin, and a 4- IBB intracellular region; and a polynucleotide encoding IL- 15; and optionally a polynucleotide encoding CCL19, vectors, pharmaceutical compositions comprising the nucleic acid molecules, and methods of using the engineered immune cells.

公开(公告)号：WO2022214978A1

公开(公告)日：2022-10-13

申请号：PCT/IB2022/053188

申请日：2022-04-06

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： MAY, Chad ,  DUBRIDGE, Robert B. ,  VINOGRADOVA, Maia ,  PANCHAL, Anand

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K16/46 ,  A61K39/00

摘要： The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.

公开(公告)号：WO2022190060A1

公开(公告)日：2022-09-15

申请号：PCT/IB2022/052214

申请日：2022-03-11

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： CRONICAN, James

IPC分类号： A61K31/451 ,  A61P25/00 ,  A61P25/26

摘要： Described herein are methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy) methyl)-piperidine-1-carboxylate (Compound (I)), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, compositions comprising Compound (I), and the use of Compound (I) for the treatment of an orexin-mediated disease or disorder, such as idiopathic hypersomnia and excessive daytime sleepiness, in a human in need thereof.

公开(公告)号：WO2022167869A2

公开(公告)日：2022-08-11

申请号：PCT/IB2022/000070

申请日：2022-02-07

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： WOLF, Adam ,  GATTERNIG, Thomas ,  MAJNERI, Paul

IPC分类号： B01L9/06 ,  G01N30/02 ,  B01L2200/023 ,  B01L2200/0631 ,  B01L2300/043 ,  B01L2300/0832 ,  B01L3/502 ,  G01N30/24 ,  G01N30/6047

摘要： A support fixture for chromatography columns operated by a liquid handling robot includes a frame and a lid. The frame has a base and a column stand extending upward from the base. The frame also includes bores extending vertically between the base and an upper portion of the column stand. The lid is movably attached to the upper portion of the column stand and has openings that axially align with the bores in the frame. The lid is movable between an open position configured to allow insertion of chromatography columns into the bores and a closed position configured to secure the chromatography columns in the bores.

公开(公告)号：WO2022130013A1

公开(公告)日：2022-06-23

申请号：PCT/IB2021/000868

申请日：2021-12-14

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： CHEN, Tseng-hui, Timothy ,  CULP, Patricia, A.

IPC分类号： C07K16/28 ,  C07K16/32 ,  A61P35/00

摘要： The present disclosure, in some aspects, provides Co-stimulatory Conditional Bispecific Redirected Activation constructs, or "co-stim COBRA," that are administered in an active prodrug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well and immune cells (e.g., one or more types of immune cells), thus recruiting immune cells to tumor, resulting in treatment.

公开(公告)号：WO2022066917A1

公开(公告)日：2022-03-31

申请号：PCT/US2021/051764

申请日：2021-09-23

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  TON-NU, Thu ,  WANG, Haixia ,  WANG, Xioalun

发明人： TON-NU, Thu ,  WANG, Haixia ,  WANG, Xioalun

IPC分类号： A61P29/00 ,  A61P35/00 ,  C07D213/74 ,  C07D213/82 ,  C07D241/14 ,  C07D241/26 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D498/04 ,  A61K31/44 ,  A61K31/4427

摘要： Disclosed are compounds of Formula (1) and pharmaceutically acceptable salts thereof, wherein L1, R1, R2, R3, R4, R6, R7, R8, R9 and X5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with RIPK2.

公开(公告)号：WO2022058791A1

公开(公告)日：2022-03-24

申请号：PCT/IB2021/000628

申请日：2021-09-17

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： ARKILO, Dimitrios ,  ATIENZA, Joy ,  LAURENZA, Antonio ,  SCHIFFER, Hans ,  TAUSCHER, Johannes ,  YIN, Wei

IPC分类号： A61K31/53 ,  A61K9/00 ,  A61P25/18 ,  A61K45/06

摘要： Methods of treating schizophrenia comprising administering at least one compound chosen from Compound (I): and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising at least one compound chosen from Compound (I) and pharmaceutically acceptable salts thereof are also disclosed.

公开(公告)号：WO2022014672A1

公开(公告)日：2022-01-20

申请号：PCT/JP2021/026607

申请日：2021-07-15

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： GREENBLATT Elliot ,  SIEGELMAN Jenifer ,  YARDIBI Ozlem

IPC分类号： G06T7/00 ,  G06T7/11

摘要： A method (600) for scoring image data using error prediction includes receiving a frame of image data (20) representative of an intensity of a condition. The method also includes processing, using a neural network (110), the frame of image data. The method also includes predicting, by the neural network, an intensity value (120) of the condition based on the frame of image data. The method also includes predicting, by the neural network, an error value (130) of the predicted intensity value. The error value is representative of a difference between the predicted intensity value and a ground truth intensity value (122) of the frame of image data.